TD Cowen Initiates Coverage on vTv Therapeutics (NASDAQ:VTVT)

Analysts at TD Cowen initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage set a “buy” rating and a $67.00 price target on the biotechnology company’s stock. TD Cowen’s target price points to a potential upside of 69.19% from the stock’s previous close.

A number of other research analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $47.00 price objective (up previously from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. BTIG Research assumed coverage on vTv Therapeutics in a report on Wednesday, November 19th. They set a “buy” rating and a $40.00 price target for the company. Wall Street Zen raised vTv Therapeutics to a “sell” rating in a research report on Saturday, December 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. Finally, Cowen assumed coverage on shares of vTv Therapeutics in a research note on Monday. They set a “buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.33.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $39.60 on Monday. The stock has a market cap of $156.02 million, a PE ratio of -11.93 and a beta of 0.48. vTv Therapeutics has a fifty-two week low of $13.20 and a fifty-two week high of $41.49. The firm’s 50-day simple moving average is $30.51 and its two-hundred day simple moving average is $22.39.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

Institutional Inflows and Outflows

A hedge fund recently raised its stake in vTv Therapeutics stock. Baker BROS. Advisors LP boosted its stake in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 148,314 shares of the biotechnology company’s stock after purchasing an additional 51,000 shares during the period. Baker BROS. Advisors LP owned approximately 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent quarter. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.